or Try an Advanced Search...

    Technical Analysis for PHAT - Phathom Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 9.34 -1.16% -0.11
    PHAT closed down 1.16 percent on Friday, November 22, 2024, on 86 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical PHAT trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Gapped Down Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Wide Bands Range Expansion -1.16%
    Oversold Stochastic Weakness -1.16%
    180 Bearish Setup Bearish Swing Setup 6.99%
    Calm After Storm Range Contraction 6.99%
    Outside Day Range Expansion 6.99%
    Wide Bands Range Expansion 6.99%
    Oversold Stochastic Weakness 6.99%
    Older End-of-Day Signals for PHAT ...

       Recent Intraday Alerts

    Alert Time
    Up 5% 1 day ago
    10 DMA Resistance 1 day ago
    Up 3% 1 day ago
    Gap Down Partially Closed 1 day ago
    Gap Down Closed 1 day ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    PHAT Chart by TradingView
    Basic chart:

    Profile

    Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Life Sciences Acid Natural Sciences Medication Gastrointestinal Disorders Potassium Gastrointestinal Disease Tadataka Yamada

    Is PHAT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 19 Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know
    Nov 10 Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript
    Nov 8 Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
    Nov 7 Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates
    Nov 7 Phathom Pharmaceuticals GAAP EPS of -$1.32 beats by $0.21, revenue of $16.4M beats by $3.99M
    Nov 7 Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
    Nov 1 Investors bid Phathom Pharmaceuticals (NASDAQ:PHAT) up US$75m despite increasing losses YoY, taking one-year return to 96%
    Oct 28 Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
    Oct 27 Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting
    Sep 27 Phathom's Voquezna: A Breakthrough Drug Facing Marketing Challenges
    See more PHAT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 19.71
    52 Week Low 6.065
    Average Volume 1,430,406
    200-Day Moving Average 12.20
    50-Day Moving Average 15.65
    20-Day Moving Average 13.71
    10-Day Moving Average 9.60
    Average True Range 1.36
    RSI (14) 30.56
    ADX 35.0
    +DI 13.58
    -DI 30.79
    Chandelier Exit (Long, 3 ATRs) 15.43
    Chandelier Exit (Short, 3 ATRs) 12.57
    Upper Bollinger Bands 22.15
    Lower Bollinger Band 5.27
    Percent B (%b) 0.24
    BandWidth 123.15
    MACD Line -2.13
    MACD Signal Line -1.62
    MACD Histogram -0.509
    Fundamentals Value
    Market Cap 534.74 Million
    Num Shares 57.3 Million
    EPS -3.81
    Price-to-Earnings (P/E) Ratio -2.45
    Price-to-Sales 0.00
    Price-to-Book 25.37
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 10.89
    Resistance 3 (R3) 10.93 10.45 10.63
    Resistance 2 (R2) 10.45 10.06 10.43 10.54
    Resistance 1 (R1) 9.90 9.82 10.18 9.86 10.46
    Pivot Point 9.42 9.42 9.56 9.40 9.42
    Support 1 (S1) 8.87 9.03 9.15 8.83 8.22
    Support 2 (S2) 8.39 8.79 8.37 8.14
    Support 3 (S3) 7.84 8.39 8.05
    Support 4 (S4) 7.80